LLY Chart

1 Month

	Date	Diff
	2025-04-22	+1.16 %
Eli Lilly & Co.'s stock rose by 1.16% following positive results from its weight-loss pill, which demonstrated effectiveness comparable to Novo Nordisk's Ozempic, causing Novo Nordisk's stock to decline significantly.
	2025-04-21	-2.61 %
Eli Lilly & Co (LLY) stock experienced a decline of -2.61% attributed to broader market trends and investment strategy adjustments by funds like Eaton Vance Worldwide Health Sciences Fund, which involves reducing positions in various health-related companies amidst fluctuating investor sentiment.
	2025-04-17	+14.3 %
Eli Lilly & Co. (LLY) stock soared 14.3% after trial data indicated its experimental weight-loss pill, orforglipron, demonstrated comparable efficacy to the popular Ozempic injection, pushing the company closer to a potential oral alternative in the obesity treatment market. The stock's increase is attributed to favorable results from the trial, showing significant weight loss and improved blood sugar levels, which could position Lilly as a leader in the evolving weight-loss drug market. Eli Lilly & Co. (LLY) stock surged by 14.3% following positive results from late-stage trials of its oral obesity medication orforglipron, which successfully lowered blood sugar levels in patients with Type 2 diabetes and facilitated weight loss, positioning it as a potentially more convenient alternative to existing GLP-1 injection therapies.
	2025-04-16	-2.94 %
Eli Lilly and Company (LLY) stock fell by 2.94% following a downgrade of its price target by Guggenheim from $973.00 to $928.00, despite maintaining a "buy" rating, reflecting investor concerns about potential growth amidst mixed analyst sentiments and recent earnings results that missed expectations.
	2025-04-15	+0.38 %
Eli Lilly & Co (LLY) stock rose by 0.38% following an upgrade in Q1 2026 earnings per share estimates by Zacks Research, which increased its forecast from $6.22 to $6.30, reflecting growing analyst confidence in the company's financial performance.
	2025-04-14	+3 %
Eli Lilly & Co (LLY) stock rose by 3.0% following Pfizer's decision to discontinue the development of danuglipron, which may have positively influenced investor sentiment towards Eli Lilly and other companies in the sector.
	2025-04-09	+3.78 %
Eli Lilly & Co. (LLY) shares rose 3.78% amidst a heightened interest in pharmaceutical stocks driven by trading volume increases and market dynamics, likely influenced by the company's strong product pipeline and robust performance in recent trading sessions.
	2025-04-08	+0.35 %
Eli Lilly & Co (LLY) stock rose by 0.35% due to its strong consensus rating, higher revenue and earnings compared to Exicure, and a favorable institutional ownership profile which suggests confidence from large investors in its long-term growth potential.
	2025-04-03	-3.56 %
Eli Lilly & Co (LLY) stock fell by 3.56% amid news that Sangamo Therapeutics announced a licensing agreement with the company, which may have raised concerns among investors about the potential implications or costs associated with the deal.
	2025-04-01	-2.5 %
Eli Lilly & Co. (LLY) stock fell by 2.5% amid concerns about potential tariffs on pharmaceuticals proposed by the Trump administration, which could disrupt existing supply chains and raise production costs for companies heavily reliant on imported ingredients.
	2025-03-27	-0.62 %
Eli Lilly & Co (LLY) saw a decline of 0.62%, trading down to $851.85 amid fluctuations in the pharmaceutical sector influenced by trading volumes and market conditions. The drop in Eli Lilly & Co's stock price could be attributed to overall market trends affecting pharmaceutical stocks, as well as potential concerns regarding trading volume and market sentiment. Eli Lilly & Co (LLY) stock experienced a decline of 0.62% last night, amidst broader market dynamics and competition in the biotech field, particularly in the context of advancements and approvals in treatments from other companies.
	2025-03-25	-1.45 %
Eli Lilly & Co (LLY) stock fell by 1.45% mainly due to a general downtrend in the healthcare sector, influenced by market dynamics and regulatory changes affecting medical stocks.
	2025-03-19	+1.76 %
Eli Lilly & Co. (LLY) stock rose by 1.76% to $826.35, likely due to strong trading volume and investor interest among pharmaceutical stocks as part of a broader trend in the healthcare sector.
	2025-03-13	-2.46 %
Eli Lilly & Co (LLY) stock decreased by 2.46% amidst a broader decline in weight loss drug stocks due to increasing competition in the GLP-1 market, as rivals like Zealand Pharma and Roche are developing next-generation treatments with better weight-loss results, alongside regulatory changes impacting the availability of off-brand GLP-1 medications.
	2025-03-11	-0.69 %
Eli Lilly & Co (LLY) stock fell by 0.57% despite positive clinical trial results for their partnered drug, baricitinib, in treating severe alopecia areata in adolescents, possibly due to profit-taking or market volatility rather than the implications of the study itself.
	2025-02-25	+2.31 %
Eli Lilly & Co (LLY) stock rose by 2.31% to $874.12, fueled by increased trading volume and interest in pharmaceutical stocks, as indicated by market activity involving high dollar volumes for leading pharmaceutical companies.
	2025-02-07	+0.91 %
Eli Lilly & Co. (LLY) stock rose by 0.91% due to the company reporting strong fourth-quarter earnings that exceeded analysts' expectations, with adjusted earnings per share of $5.32 and revenues of $13.53 billion, both reflecting significant year-over-year growth.
	2025-02-06	+3.35 %
Eli Lilly & Co (LLY) stock rose by 3.35% due to positive market sentiment driven by strong corporate earnings reports and a favorable forecast coming in line with estimates.
	2025-02-05	+1.95 %
Eli Lilly & Co. (LLY) stock rose 1.95% due in part to positive updates such as an increased quarterly dividend and significant institutional investment adjustments, reflecting investor confidence in the company's growth and earnings potential. Eli Lilly & Co (LLY) stock rose 1.95% ahead of its upcoming fourth-quarter earnings report, with analysts anticipating strong EPS and revenue figures, contributing to an overall positive sentiment and a year-to-date increase of 8.22%.
	2025-02-04	+1.93 %
Eli Lilly and Company (LLY) stock rose by 1.93% after Truist Financial raised their price target for the stock from $1,029 to $1,038, reinforcing a buy rating, alongside positive ratings and target adjustments from several other financial analysts.
	2025-02-03	-0.08 %
Eli Lilly & Co (LLY) stock experienced a slight decline of -0.08%, likely influenced by ongoing developments and competition in the pharmaceutical sector, particularly related to AI-driven drug discovery initiatives from tech companies like Alphabet's Isomorphic Labs.
	2025-01-27	+2.9 %
Eli Lilly and Company (LLY) stock rose by 2.9% last night, driven by increased institutional investor holdings and positive analyst ratings, indicating strong market confidence in the company's performance and future prospects. Eli Lilly & Co (LLY) stock rose 2.9% likely due to positive sentiment from institutional investment activity, including recent buyback programs indicating perceived undervaluation, alongside increased analyst confidence reflected in recent upgrades and target price adjustments. Eli Lilly & Co. (LLY) stock rose 2.9% following notable institutional investment activity, including RFG Advisory LLC increasing its stake by 13.4% in the fourth quarter and several other hedge funds boosting their positions, indicating strong investor confidence and perceived growth potential in the company.
	2025-01-21	+2.29 %
Eli Lilly & Co. (NYSE: LLY) stock rose by 2.29% due to positive expectations for its future revenue growth driven by strong demand for its diabetes and weight-loss treatments, alongside optimistic forecasts for annual revenue increases despite recent shortfalls in sales.
	2025-01-14	-6.59 %
Eli Lilly & Co (LLY) stock fell by 6.59% after the company projected its 2024 worldwide revenue to be approximately $45.0 billion, which is below the market consensus of $45.50 billion, indicating weaker-than-expected financial expectations. Eli Lilly & Co. (LLY) stock fell by 6.59% due to a weak earnings update that negatively impacted its share price and affected related health care stocks in Europe. Eli Lilly & Co (LLY) stock experienced a decline of 6.59% due to disappointing quarterly earnings, which missed consensus estimates and reflected lower-than-expected revenue.
	2025-01-13	-0.3 %
Eli Lilly & Co (LLY) stock fell by 0.3% due to a combination of disappointing earnings results, where the company missed consensus EPS estimates and revenue predictions, despite showing strong year-over-year growth.
	2025-01-10	+1.61 %
Eli Lilly & Co. (LLY) stock increased by 1.61% due to the anticipation of significant market opportunities in Alzheimer's disease treatments, particularly with their recently approved drug Kisunla and the upcoming trial results for their follow-on drug, remternetug, which could boost investor confidence and expectations for sales growth in this burgeoning market.
	2025-01-06	-2.16 %
Eli Lilly & Co. (NYSE: LLY) stock fell by 2.16% following reports of a decrease in institutional investment positions, a quarterly earnings miss, and lowered revenue projections, which contributed to a negative market sentiment around the company's performance. Eli Lilly & Co. (LLY) shares fell by 2.16% as the market reacted to a missed earnings estimate and lower-than-expected revenue for the last quarter, coupled with a recent insider sale of shares, which may have raised concerns among investors. Eli Lilly & Co. (LLY) stock fell by 2.16% following disappointing quarterly earnings that missed consensus estimates, including earnings per share and revenue figures. Eli Lilly & Co. (LLY) stock decreased by 2.16% due to disappointing quarterly earnings results that fell short of analyst expectations, with a reported EPS of $1.18 compared to the consensus of $1.52, and revenue of $11.44 billion, below the expected $12.09 billion.
	2025-01-03	+0.5 %
Eli Lilly & Co. (LLY) stock rose by 0.5% due to increased institutional investor interest, including a 19.2% stake increase by Versant Capital Management, alongside a recent announcement of a share buyback plan indicative of management's confidence in the stock's value. Eli Lilly and Company (LLY) stock was up 0.5% due to positive analyst upgrades and a boost in its quarterly dividend, which indicates confidence in the company's valuation and financial health.
	2024-12-31	-0.24 %
Eli Lilly & Co. (LLY) stock fell by 0.24% recently, potentially due to ongoing concerns in the healthcare sector and broader market volatility affecting investor sentiment. Eli Lilly & Co (LLY) stock experienced a decline of 0.24%, which was contributed to broader market trends and investor sentiment, alongside recent adjustments in stock valuations surrounding the healthcare sector. Eli Lilly & Co (LLY) stock declined by 0.24% recently, possibly due to overall market trends, news affecting the pharmaceutical sector, or investor reactions to recent changes in trading activity. Eli Lilly & Co (LLY) stock experienced a decline of 0.24%, which may be attributed to broader market trends or investor reactions to external economic factors, rather than specific company news. Eli Lilly & Co. (LLY) stock experienced a decrease of 0.24% due to disappointing quarterly earnings, where the company missed analysts' expectations for EPS and revenue, which could have affected investor confidence.
	2024-12-13	+0.87 %
Eli Lilly & Co (LLY) stock rose 0.87% last night, contributing to a year-to-date increase of 32.11%, likely driven by its strong performance attracting interest in ETFs that hold substantial stakes in the company.
	2024-12-10	-0.5 %
Eli Lilly & Co (LLY) stock fell by 0.5% despite the company's $15 billion share buyback plan and a 15% dividend increase, as mixed technical signals may have influenced investor sentiment. Eli Lilly & Co (LLY) stock decreased by 0.5% after the company announced results from the Phase 3 BRUIN CLL-321 trial for pirtobrutinib, which likely did not meet investor expectations or showed less promising results than anticipated.
	2024-12-06	+0.13 %
Eli Lilly & Co (LLY) stock rose by 0.13% following the announcement of a $3 billion expansion of its Kenosha County manufacturing facility, which aims to meet growing demand for diabetes and obesity medications, create 750 jobs, and enhance production capabilities. The increase in stock is attributed to investor confidence in the company's strategic investments and growth in manufacturing operations.
	2024-11-21	-0.46 %
Eli Lilly and Co. (LLY) stock has experienced a recent decline of 0.46%, contributing to a 17.57% drop over the past month despite a strong annual increase of 26.04%, likely due to market pressures and lower trading prices compared to its summer highs.
	2024-11-07	+2.71 %
Eli Lilly & Co. (LLY) stock rose 2.71% after experiencing a dip of 0.8% earlier due to price target adjustments by Deutsche Bank and Barclays, indicating ongoing institutional interest and a generally favorable outlook despite recent earnings misses. The stock's increase can be attributed to strong support from multiple analysts who maintain buy ratings and increased price targets, alongside significant institutional investment in the company.
	2024-11-05	-0.01 %
Eli Lilly & Co (LLY) stock saw a slight decline of -0.01% due to a general downturn in broader market conditions and potential investor concerns regarding competition and supply in the obesity medication market. Eli Lilly & Co (LLY) stock dipped slightly by 0.01% following reports that the FDA declared its weight-loss and diabetes medication, tirzepatide (Zepbound/Mounjaro), is no longer considered in short supply, which could impact market dynamics for competing companies like Hims&Hers Health that are capitalizing on the demand for GLP-1 drugs.
	2024-11-04	-1.56 %
Eli Lilly & Co. (LLY) stock declined by 1.56% due to concerns over proposed policy changes by Vice President Kamala Harris, which could negatively impact profit margins in the pharmaceutical sector, particularly regarding high prescription drug prices. Eli Lilly & Co (LLY) stock fell by 1.56% amid uncertainties surrounding the upcoming election, with concerns that Vice President Kamala Harris's proposed policies to lower prescription drug prices might negatively impact the profitability of pharmaceutical companies like Eli Lilly.
	2024-10-30	-6.28 %
Eli Lilly & Co (LLY) stock dropped 6.28% following the release of disappointing third-quarter earnings that fell short of expectations and a reduction in guidance for 2024. Eli Lilly & Co (LLY) stock experienced a 6.28% decline, likely due to investor reaction to the upcoming third-quarter earnings report, despite a brief pre-market increase. Eli Lilly & Co (LLY) stock fell 6.28% after the company reported disappointing third-quarter earnings, with revenue of $11.44 billion falling short of expectations, and subsequently lowered its guidance for 2024.
	2024-10-29	+0.89 %
Eli Lilly & Co (LLY) stock rose 0.89% ahead of its third-quarter earnings report, with expectations of $1.45 EPS and $12.10 billion in revenues, likely driven by positive market sentiment toward its weight-loss drug developments and significant year-to-date gains of 58.31%. Eli Lilly & Co (LLY) stock rose 0.89% due to strong institutional interest, including significant holdings and upgrades by analysts, following the company's impressive quarterly earnings that exceeded expectations and a recently announced dividend. Eli Lilly & Co (NYSE: LLY) stock rose by 0.89% following significant increases in stake by multiple institutional investors, indicating strong market confidence and favorable sentiment around the company's performance and growth potential. Eli Lilly & Co. (LLY) stock rose by 0.89% as it outperformed Novo Nordisk A/S in the obesity drug market, although analysts predict Novo Nordisk may start to catch up soon. The stock's increase is likely due to its strong performance and competitive advantage in the rapidly growing obesity drug sector. Eli Lilly & Co (LLY) stock rose by 0.89% partly due to strong quarterly earnings that exceeded analysts' expectations and a series of positive adjustments to its target stock price from various investment firms, suggesting robust investor confidence in the company's future performance.